FDA updates its list of drugs without generics

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

FDA updates its list of drugs without generics

INICIO/Directrices | Posted 12/01/2018 0 Post your comment

The US Food and Drug Administration (FDA) announced in December 2017 that it had updated its list of drugs without generics.

The update is part of the agency’s continuing efforts to increase competition and bring down the price of prescription drugs.

FDA first published the list of brand-name drugs that no longer have patent protection or exclusivity in the US and that do not have approved generics in June 2017 [1]. This list includes approved new drug applications (NDA) drug products that are no longer protected by patents or exclusivities, and for which FDA has not approved an abbreviated new drug application (ANDA) referencing that NDA product.

List of off-patent, off-exclusivity drugs without an approved generic
Date: December 2017
www.fda.gov/downloads/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/UCM564441.pdf

The list is divided into two parts. Part I contains drug products for which FDA could immediately accept an ANDA without prior discussion. Part II identifies drug products involving potential legal, regulatory, or scientific issues which should be addressed with the agency prior to submission of an ANDA.

For this updated list FDA used different methodology. Under the updated methodology, the list is organized based on drug products, not active ingredients. This means that an active and approved NDA for a particular active ingredient and dosage form will be included on the list if there are no approved ANDAs for at least one drug product for that active ingredient and dosage form approved in the NDA, even if there are approved ANDAs that reference a drug product in a different NDA with the same active ingredient and dosage form.

FDA says that it ‘maintains this list to improve transparency and encourage the development and submission of ANDAs in markets with little competition’. The list is updated every six months and is available in both PDF and Excel format.

Related article
FDA to speed up review of priority generics

Reference
1. GaBI Online - Generics and Biosimilars Initiative. FDA lists drugs without generics to increase competition [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 12]. Available from: www.gabionline.net/Generics/General/FDA-lists-drugs-without-generics-to-increase-competition

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: US FDA